
QIAGEN N.V. QGEN
Annual report 2024
added 03-14-2026
QIAGEN N.V. Operating Expenses 2011-2026 | QGEN
Annual Operating Expenses QIAGEN N.V.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 821 M | 695 M | 692 M | 734 M | 769 M | 746 M | 651 M | 704 M | 752 M | 654 M | 650 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 821 M | 650 M | 715 M |
Operating Expenses of other stocks in the Diagnostics research industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
58 M | - | -6.23 % | $ 30.6 M | ||
|
Interpace Biosciences
IDXG
|
21.8 M | $ 1.71 | 0.73 % | $ 7.5 M | ||
|
Illumina
ILMN
|
3.69 B | $ 123.79 | -0.43 % | $ 19.7 B | ||
|
Biomerica
BMRA
|
5.64 M | $ 2.13 | -2.74 % | $ 4.89 M | ||
|
Castle Biosciences
CSTL
|
59.5 M | $ 25.75 | 3.0 % | $ 715 M | ||
|
Check-Cap Ltd.
CHEK
|
14.1 M | - | - | $ 9.42 M | ||
|
Akumin
AKU
|
778 M | - | -17.87 % | $ 25.9 M | ||
|
Enzo Biochem
ENZ
|
47.4 M | - | -8.98 % | $ 14.8 K | ||
|
Oxford Immunotec Global PLC
OXFD
|
59.4 M | - | - | $ 562 M | ||
|
NeoGenomics
NEO
|
430 M | $ 8.1 | 1.76 % | $ 1.04 B | ||
|
Exact Sciences Corporation
EXAS
|
2.47 B | $ 104.91 | - | $ 19.8 B | ||
|
National Research Corporation
NRC
|
38.5 M | $ 17.51 | 1.1 % | $ 392 M | ||
|
Natera
NTRA
|
258 M | $ 200.09 | 2.46 % | $ 19.7 B | ||
|
Aspira Women's Health
AWH
|
37.1 M | - | -6.19 % | $ 10.5 M | ||
|
Co-Diagnostics
CODX
|
45.3 M | $ 4.4 | 101.83 % | $ 129 M | ||
|
Accelerate Diagnostics
AXDX
|
77.2 M | - | -61.36 % | $ 2.46 M | ||
|
OPKO Health
OPK
|
217 M | $ 1.15 | 2.68 % | $ 798 M | ||
|
Global Cord Blood Corporation
CO
|
451 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
134 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
5.91 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
983 M | - | 0.12 % | $ 80.1 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
585 M | - | - | $ 10.7 B | ||
|
Personalis
PSNL
|
44.5 M | $ 7.61 | 4.82 % | $ 451 M | ||
|
Charles River Laboratories International
CRL
|
607 M | $ 158.0 | 2.86 % | $ 7.83 B | ||
|
IQVIA Holdings
IQV
|
2.94 B | $ 166.96 | 0.54 % | $ 28.7 B | ||
|
Lantheus Holdings
LNTH
|
123 M | $ 75.73 | -0.92 % | $ 5.11 B | ||
|
Motus GI Holdings
MOTS
|
18.6 M | - | -34.28 % | $ 263 K | ||
|
IDEXX Laboratories
IDXX
|
1.3 B | $ 578.51 | 0.22 % | $ 46.5 B | ||
|
Biocept
BIOC
|
21.6 M | - | -13.05 % | $ 7.29 M | ||
|
Invitae Corporation
NVTA
|
343 M | - | - | $ 21.2 M | ||
|
BioNano Genomics
BNGO
|
41.3 M | $ 1.46 | 26.96 % | $ 1.86 M | ||
|
Medpace Holdings
MEDP
|
118 M | $ 456.93 | 0.98 % | $ 13.2 B | ||
|
Senseonics Holdings
SENS
|
61.8 M | $ 6.62 | 2.16 % | $ 276 M | ||
|
Sotera Health Company
SHC
|
309 M | $ 13.88 | 2.81 % | $ 3.94 B | ||
|
Agilent Technologies
A
|
1.99 B | $ 112.02 | 0.65 % | $ 34.1 B | ||
|
ICON Public Limited Company
ICLR
|
408 M | $ 100.35 | 0.65 % | $ 8.28 B | ||
|
Soleno Therapeutics
SLNO
|
181 M | $ 31.72 | -4.52 % | $ 1.61 B | ||
|
DarioHealth Corp.
DRIO
|
49.3 M | $ 7.5 | -6.13 % | $ 29.9 M | ||
|
Guardant Health
GH
|
226 M | $ 84.9 | -0.33 % | $ 10.6 B | ||
|
Myriad Genetics
MYGN
|
964 M | $ 4.66 | 1.75 % | $ 432 M | ||
|
Psychemedics Corporation
PMD
|
11.3 M | - | -1.84 % | $ 15.3 M | ||
|
Neuronetics
STIM
|
104 M | $ 1.6 | 10.34 % | $ 106 M | ||
|
Mettler-Toledo International
MTD
|
1.01 B | $ 1 239.07 | 2.87 % | $ 25.5 B | ||
|
CareDx, Inc
CDNA
|
411 M | $ 17.56 | 2.39 % | $ 936 M | ||
|
ENDRA Life Sciences
NDRA
|
10.8 M | $ 3.48 | 0.87 % | $ 1.87 M | ||
|
Thermo Fisher Scientific
TMO
|
7.15 B | $ 478.12 | 0.79 % | $ 180 B | ||
|
Celcuity
CELC
|
113 M | $ 106.75 | 0.67 % | $ 4.21 B | ||
|
Chembio Diagnostics
CEMI
|
28.5 M | - | 0.22 % | $ 16.8 M | ||
|
Laboratory Corporation of America Holdings
LH
|
1.87 B | $ 264.42 | 0.54 % | $ 22 B |